X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 18.1 25.1 72.3% View Chart
P/BV x 3.9 3.3 117.3% View Chart
Dividend Yield % 1.6 0.7 237.4%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,484374 663.4%   
Low Rs918129 712.3%   
Sales per share (Unadj.) Rs142.3197.8 71.9%  
Earnings per share (Unadj.) Rs41.921.2 197.5%  
Cash flow per share (Unadj.) Rs46.334.7 133.4%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %0.60.8 74.0%  
Book value per share (Unadj.) Rs161.5179.9 89.8%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.01.3 939.8%   
Avg P/E ratio x40.611.9 342.2%  
P/CF ratio (eoy) x36.77.2 506.5%  
Price / Book Value ratio x10.51.4 752.8%  
Dividend payout %23.99.4 253.2%   
Avg Mkt Cap Rs m451,52520,306 2,223.6%   
No. of employees `0003.70.8 447.3%   
Total wages/salary Rs m3,6495,355 68.1%   
Avg. sales/employee Rs Th10,184.419,252.7 52.9%   
Avg. wages/employee Rs Th984.16,459.5 15.2%   
Avg. net profit/employee Rs Th2,998.52,064.1 145.3%   
INCOME DATA
Net Sales Rs m37,76415,961 236.6%  
Other income Rs m848265 319.7%   
Total revenues Rs m38,61216,226 238.0%   
Gross profit Rs m14,1384,103 344.5%  
Depreciation Rs m1,1821,091 108.4%   
Interest Rs m23944 2.5%   
Profit before tax Rs m13,7812,334 590.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,662624 426.9%   
Profit after tax Rs m11,1191,711 649.8%  
Gross profit margin %37.425.7 145.6%  
Effective tax rate %19.326.7 72.3%   
Net profit margin %29.410.7 274.6%  
BALANCE SHEET DATA
Current assets Rs m30,94711,018 280.9%   
Current liabilities Rs m5,1959,517 54.6%   
Net working cap to sales %68.29.4 725.1%  
Current ratio x6.01.2 514.5%  
Inventory Days Days117110 105.7%  
Debtors Days Days8535 244.4%  
Net fixed assets Rs m17,02716,304 104.4%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m42,34112,907 328.1%   
Net worth Rs m42,87714,516 295.4%   
Long term debt Rs m54,189 0.1%   
Total assets Rs m49,68429,805 166.7%  
Interest coverage x595.03.5 17,142.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.5 141.9%   
Return on assets %22.48.9 251.7%  
Return on equity %25.911.8 220.0%  
Return on capital %32.217.5 183.6%  
Exports to sales %85.324.8 344.0%   
Imports to sales %22.93.7 613.4%   
Exports (fob) Rs m32,1983,956 813.9%   
Imports (cif) Rs m8,654596 1,451.3%   
Fx inflow Rs m32,2704,952 651.7%   
Fx outflow Rs m8,775697 1,259.3%   
Net fx Rs m23,4964,255 552.2%   
CASH FLOW
From Operations Rs m10,3792,786 372.5%  
From Investments Rs m-4,135-1,529 270.4%  
From Financial Activity Rs m-6,241-941 663.2%  
Net Cashflow Rs m3316 1.0%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  J.B.CHEMICALS  SHASUN PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS